Imiquimod
Brand Names: Zyclara, Aldara
Methodology & AI Transparency ⓘ
Imiquimod Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Imiquimod Cream, 3.75% is indicated for the topical treatment of clinically typical, visible, or palpable actinic keratoses (AK) of the face or balding scalp in immunocompetent adults.
- 2 Real-world patient consensus: Zero-PHI community consensus: 90% favorable across 20 logged regimens (Zyclara, Aldara).
- 3 Typical cash cost range: Public pharmacy ledger: $20.81 low cash benchmark vs. $50.98 chain retail average ($0.5940/unit CMS NADAC).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Imiquimod include nausea (11.5%), headache (10.1%), fatigue (5.6%).
Ask our AI Specialists anything about Imiquimod
Imiquimod Mechanism, CYP450 Pathways & DailyMed Monograph
Imiquimod Cream, 3.75% is indicated for the topical treatment of clinically typical, visible, or palpable actinic keratoses (AK) of the face or balding scalp in immunocompetent adults. ( 1.1 ) Imiquimod Cream, 3.75% is indicated for the topical treatment of external genital and perianal warts (EGW) in immunocompetent patients 12 years of age or older. ( 1.2 ) 1.1 Actinic Keratosis Imiquimod Cream, 3.75% is indicated for the topical treatment of clinically typical, visible or palpable actinic keratoses (AK) of the face or balding scalp in immunocompetent adults.
12.1 Mechanism of Action The mechanism of action of Imiquimod Cream in the treatment of AK and EGW is unknown. In clinical regimens (12.5 mg/.25g Cream, 50 mg/g Cream), Imiquimod executes increased cytokine activity target modulation documented under federal RxCUI 967017 and DailyMed 2025-06-03 labeling.
Systemic exposure to Imiquimod reflects < 5% transdermal or mucosal systemic uptake from Imiquimod absorption kinetics and local esterase/enzymatic cleavage of imiquimod with minimal hepatic cytochrome burden, sustaining receptor engagement across a Negligible circulating terminal half-life following local Imiquimod application half-life window (initial local symptom modulation in 30–90 minutes; full tissue response over 1–3 weeks (imiquimod) response profile).
Dosing protocols (12.5 mg/.25g Cream or 50 mg/g Cream or 37.5 mg/g Cream or 2.5 mg/g Cream or 5% Cream) balance efficacy (90.00% patient satisfaction across 20 logs) against nausea (11.5% of reports), headache (10.1% of reports), application-site irritation (6.2% of reports), with strict avoidance in contraindicated in patients with prior serious allergic response to imiquimod (ndc 68682-272); severe baseline organ impairment where imiquimod accumulation exceeds safe therapeutic margins.
Reconcile eGFR-adjusted medications before escalating Imiquimod in polypharmacy regimens.
Botanical enzyme modulators may alter oral first-pass exposure of Imiquimod; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Imiquimod (NDC 68682-272)
- Severe baseline organ impairment where Imiquimod accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (20 Reports)
Imiquimod Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Imiquimod)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of imiquimod in the management of lentigo: What a 283-Participant Study Found Imiquimod reduces the lentigo maligna surface after 1 month of treatment, without a higher risk of intralesional excision and with a positive aesthetic outcome. Journal of the European Academy of Dermatology and Venereology : JEADV • 2023-09-15 • Phase III Randomized Trial | N = 283 | 93/100 | PMID 37114291 ↗ |
| Can This Approach Help? Inside the Latest Research on Skin-applied imiquimod versus surgery for vulvar intraepithelial neoplasia: a Imiquimod is a safe, effective, and well accepted alternative to surgery for women with vHSIL and can be considered as first-line treatment. Lancet (London, England) • 2022-05-07 • Phase III Randomized Trial | N = 110 | 82/100 | PMID 35483400 ↗ |
| Can This Approach Help? Inside the Latest Research on Risk factors for recurrence of vulvar high-grade squamous intra-epithelial Applied to the skin imiquimod and surgical treatment of vulvar HSIL are effective in long-term follow-up, with recurrences occurring in 20% to 33% of patients within 5 years. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society • 2026-04-15 • Phase III Randomized Trial | N = 80 | 82/100 | PMID 41791272 ↗ |
| Radiotherapy vs. Imiquimod: Which Works Better for Complex lentigo maligna: A phase 3 randomized clinical trial? Both radiotherapy and imiquimod are efficient and well-tolerated treatments for lentigo maligna. Journal of the American Academy of Dermatology • 2025-11-15 • Phase III Randomized Trial | N = 126 | 82/100 | PMID 40683357 ↗ |
Imiquimod Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.5940/unit (~$17.82/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $20.81 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $50.98 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 20 Anonymous DotMD Community Micro-Logs | $23.93 / mo | View logs ↓ |
Imiquimod Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Imiquimod RxNorm Concept ID | 967017 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.5940 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $50.98 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $20.81 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 90.00% Worth It (20 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Imiquimod Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Imiquimod: FDA labeling (2025-06-03, NDC 68682-272), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Imiquimod community threads and patient logs by age, biological sex, dosage, and treatment duration.